Ceftriaxone

Chemical formula: C₁₈H₁₈N₈O₇S₃  Molecular mass: 554.58 g/mol  PubChem compound: 5479530

Therapeutic indications

Ceftriaxone is indicated for:

Community acquired pneumonia, acute exacerbations of chronic obstructive pulmonary disease

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Community acquired pneumonia
Acute exacerbation of chronic obstructive airways disease
and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Intra-abdominal infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Infectious disease of abdomen and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Urinary tract infectious disease and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Hospital acquired pneumonia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Nosocomial pneumonia and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated skin and soft tissue infections, infections of bones and joints

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Soft tissue infection
Infection of bone
Infectious disorder of joint
and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Neutropenic fever due to bacterial infection

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Febrile neutropenia and additionally Bacterial infectious disease and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial endocarditis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Bacterial endocarditis and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Bacterial meningitis and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute otitis media

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Acute otitis media and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pre-operative prophylaxis of surgical site infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Preventive procedure and additionally Surgical procedure

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Gonorrhoea

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Gonorrhea

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Syphilis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Syphilis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Disseminated Lyme borreliosis (early [Stage II] and late [Stage III])

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Disseminated Lyme borreliosis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Intra-abdominal infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Infectious disease of abdomen and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Urinary tract infectious disease and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Community acquired pneumonia, hospital acquired pneumonia

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Community acquired pneumonia
Nosocomial pneumonia
and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated skin and soft tissue infections, infections of bones and joints

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Soft tissue infection
Infection of bone
Infectious disorder of joint
and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Neutropenic fever due to bacterial infection

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Febrile neutropenia and additionally Bacterial infectious disease and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Bacterial meningitis and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial endocarditis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Bacterial endocarditis and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute otitis media

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Acute otitis media and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pre-operative prophylaxis of surgical site infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Preventive procedure and additionally Surgical procedure

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Syphilis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Syphilis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Disseminated Lyme borreliosis (early [Stage II] and late [Stage III])

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Disseminated Lyme borreliosis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Intra-abdominal infections

Population group: only newborns (0 - 40 days old)

Infectious disease of abdomen and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only newborns (0 - 40 days old)

Urinary tract infectious disease and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Community acquired pneumonia, hospital acquired pneumonia

Population group: only newborns (0 - 40 days old)

at least one of
Community acquired pneumonia
Nosocomial pneumonia
and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated skin and soft tissue infections, infections of bones and joints

Population group: only newborns (0 - 40 days old)

at least one of
Soft tissue infection
Infection of bone
Infectious disorder of joint
and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Neutropenic fever due to bacterial infection

Population group: only newborns (0 - 40 days old)

Febrile neutropenia and additionally Bacterial infectious disease and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only newborns (0 - 40 days old)

Bacterial meningitis and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial endocarditis

Population group: only newborns (0 - 40 days old)

Bacterial endocarditis and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute otitis media

Population group: only newborns (0 - 40 days old)

Acute otitis media and additionally at least one of
Ceftriaxone susceptible species
Ceftriaxone susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pre-operative prophylaxis of surgical site infections

Population group: only newborns (0 - 40 days old)

Preventive procedure and additionally Surgical procedure

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Syphilis

Population group: only newborns (0 - 40 days old)

Syphilis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Ceftriaxone is contraindicated in the following cases:

Hypersensitivity to cephalosporins, history of hypersensitivity to penicillins, monobactams and carbapenems

at least one of
Cephalosporin allergy
Allergy to penicillin
Monobactam allergy
Carbapenem allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: CEFTRIAXONE Powder for solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈